Metabolic dysfunction-associated steatohepatitis
Therapeutic area
Endocrinology
Rare disease
No
- Definition
- Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis or NASH) is a type of fatty liver disease. It often develops due to a metabolic disorder, such as obesity or diabetes, resulting in a toxic buildup of fat in the liver. It is the most severe form of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as nonalcoholic fatty liver disease or NAFLD).
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Metabolic dysfunction-associated steatohepatitis
- Therapeutic area
- Endocrinology
- metabolic dysfunction-associated steatohepatitis
- MASH
- NASH
- NASH - nonalcoholic steatohepatitis
- non-alcoholic steatohepatitis
- nonalcoholic steatohepatitis
- Disease mechanisms
- Inflammatory
- Severity
- Moderate
- Endocrinology
- Gastroenterology
- MONDO ID
- MONDO:0007027
- Parent condition
- MONDO:0002251
Related records
Broader conditions (12)
- Digestive system disorder
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Endocrine system disorder
- Fatty liver disease
- Hepatitis
- Hepatobiliary disorder
- Human disease
- Inflammatory disease
- Liver disorder
- Metabolic dysfunction-associated steatotic liver disease
Trials (602)
- "Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".
- 2-Week Study In People With Nonalcoholic Fatty Liver Disease
- A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers
- A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
- A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
- A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)
- A Clinical Trial of BGT-002 Tablets in Subjects With Nonalcoholic Steatohepatitis
- A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH
- A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
- A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects
- A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
- A Microdose Trial Investigating Binding of [68Ga]Ga-DOTA-CYS-ATH001 in Healthy Subjects and Different Patient Groups.
- A Multi-country, Cross-sectional Quantitative Study Exploring Awareness, Understanding, and Perceptions of the Relation Between Cardiorenal Metabolic Conditions and MASLD/MASH Among Healthcare Providers, People With MASLD/MASH, and At-risk Population
- A Multicenter, Double-blind, Placebo-randomized Controlled Clinical Study on the Treatment of Non-alcoholic Steatohepatitis With Tibetan Drug Langqing Atar
- A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH
- A One-Year, Randomized, Double-Blind, Placebo-Controlled Trial of Rosiglitazone in Non-Alcoholic Steatohepatitis
- A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of VSA006 in Chinese NASH Patients
- A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH
- A Phase 2b Study of Icosabutate in Fatty Liver Disease
- A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
Approved drugs (1)
- Resmetirom
Drugs in development (80)
- Aldafermin Phase 2
- ASP-9831 Phase 2
- Atorvastatin Phase 2
- Belapectin Phase 2
- Betaine Phase 2
- Caffeine Phase 1
- Cenicriviroc Phase 3
- Chiglitazar Phase 2
- Cilofexor Phase 2
- Clesacostat Phase 2
- Colesevelam hydrochloride Phase 2
- Cudetaxestat Phase 1
- Dapagliflozin Phase 3
- Digoxin Phase 2
- Efinopegdutide Phase 2
- Efruxifermin Phase 3
- Elafibranor Phase 2
- Elobixibat Phase 2
- Emricasan Phase 2
- Esomeprazole Phase 1
Other linked drugs (4)
- Alanine
- Hydroxychloroquine
- Taurursodiol
- Ursodiol